Intercept Pharma appoints Sandip Kapadia as CFO
Mr. Kapadia brings over 19 years of experience in building and leading finance and administration teams at life sciences companies both in the United States and internationally.
He joins Intercept from Sandoz, Inc., a division of Novartis AG, where he served as Vice President and Chief Financial Officer, North America from 2014 through 2016.
Prior to that, Mr. Kapadia held finance leadership roles at Novartis Pharmaceuticals in multiple European countries, including Chief Financial Officer for the UK/Ireland based in the United Kingdom, Chief Financial Officer for Northern Europe based in the Netherlands and Head of Finance for Emerging Growth Markets for the Oncology Business Unit based in Switzerland.
Mr. Kapadia earned his bachelor degree in business administration and accounting from Montclair State University, an M.B.A from Rutgers Graduate School of Management and is a Certified Public Accountant.
Mr. Kapadia will succeed Barbara Duncan who has served as CFO for Intercept since 2009.
Ms. Duncan has served as Company's chief financial officer since May 2009 and as treasurer since 2010. She has over 15 years of experience in the life sciences industry.
From 2001 through April 2009, Ms. Duncan served as chief financial officer and then chief executive officer at DOV Pharmaceutical, Inc., or DOV, which was sold to Euthymics Bioscience, Inc. in 2010.
Prior to joining DOV, she served as a vice president of Lehman Brothers Inc. in its corporate finance division from August 1998 to August 2001, where she provided financial advisory services primarily to companies in the life sciences and general industrial industries.
From September 1994 to August 1998, Ms. Duncan was an associate and director at SBC Warburg Dillon Read, Inc. in its corporate finance group.
She also worked for PepsiCo, Inc. from 1989 to 1992 in its international audit division, and was a certified public accountant in the audit division of Deloitte & Touche LLP from 1986 to 1989. She joined the board of directors of Medgenics in July 2015.
Ms. Duncan received her B.S. from Louisiana State University in 1985 and her M.B.A. from the Wharton School, University of Pennsylvania, in 1994. ■
LATEST MOVES FROM New York
- M&T Bank names Laura P. O'Hara senior vice president
- Akari Therapeutics to appoint David Horn Solomon as CEO
- Xylem appoints Paul Stellato as vice president
- Edward Campanella to join Arrow Financial as SVP, treasurer, and CFO
- Altaba appoints Richard L. Kauffman as director
More inside POST